Alector's 2023 10-K Highlights R&D Focus and Facility Locations

Ticker: ALEC · Form: 10-K · Filed: 2024-02-27T00:00:00.000Z

Sentiment: neutral

Topics: 10-K Filing, Biotechnology, R&D, Corporate Structure

TL;DR

**Alector's 2023 10-K is out, confirming R&D activities and facility locations, but key financial numbers aren't detailed in this snippet.**

AI Summary

Alector, Inc. filed its 10-K for the fiscal year ended December 31, 2023, on February 27, 2024. The filing indicates the company's focus on biological products and mentions research and development expenses for 2022, though specific dollar amounts are not provided in this snippet. Alector operates offices and laboratory facilities in South San Francisco, CA, and Newark, CA, and has a related party relationship with Adimab as of December 31, 2023.

Why It Matters

This regulatory filing provides essential structural and operational details for Alector, Inc., offering investors insight into its corporate activities, including its R&D commitments and physical footprint, despite lacking specific financial figures in this excerpt.

Risk Assessment

Risk Level: high — As a biological products company, Alector, Inc. faces inherent high risks associated with drug development, clinical trials, and regulatory approvals, which typically involve significant R&D expenses and uncertain outcomes.

Key Numbers

Key Players & Entities

FAQ

What is the name of the company that filed this 10-K?

The company that filed this 10-K is Alector, Inc.

What is the fiscal year end for the period covered by this 10-K?

The fiscal year end for the period covered is December 31, 2023.

When was this 10-K filing submitted to the SEC?

This 10-K filing was submitted to the SEC on February 27, 2024.

Where are Alector, Inc.'s primary business offices and laboratory facilities located?

Alector, Inc.'s primary business offices and laboratory facilities are located in South San Francisco, CA, and Newark, CA.

What is the Central Index Key (CIK) for Alector, Inc.?

The Central Index Key (CIK) for Alector, Inc. is 0001653087.

From the Filing

0000950170-24-021183.txt : 20240227 0000950170-24-021183.hdr.sgml : 20240227 20240227161901 ACCESSION NUMBER: 0000950170-24-021183 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 95 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240227 DATE AS OF CHANGE: 20240227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822933343 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 24687037 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 10-K 1 alec-20231231.htm 10-K 10-K 0001653087 December 31 true FY false P3Y 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001653087 alec:TwoThousandTwentyTwoInducementPlanMember 2022-09-22 2022-09-22 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001653087 alec:AdimabMember us-gaap:RelatedPartyMember 2023-12-31 0001653087 us-gaap:CommonStockMember 2023-12-31 0001653087 us-gaap:DomesticCountryMember 2023-01-01 2023-12-31 0001653087 alec:RestrictedStockAwardsAndRestrictedStockUnitsMember 2021-01-01 2021-12-31 0001653087 alec:TwoThousandNineteenEmployeeStockPurchasePlanMember 2023-01-01 0001653087 alec:NewarkCaliforniaMember alec:OfficesAndLaboratoryFacilitiesMember 2023-01-01 2023-12-31 0001653087 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0001653087 us-gaap:StateAndLocalJurisdictionMember 2023-01-01 2023-12-31 0001653087 us-gaap:RetainedEarningsMember 2023-12-31 0001653087 alec:SouthSanFranciscoMember alec:OfficesAndLaboratoryFacilitiesMember 2021-01-01 2021-12-31 0001653087 srt:MaximumMember alec:GskMember 2021-07-01 0001653087 alec:TwoThousandFourteenAdimabAgreementMember us-gaap:RelatedPartyMember 2023-01-01 2023-12-31 0001653087 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001653087 us-gaap:EmployeeStockMember 2022-01-01 2022-12-31 0001653087 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001653087 2023-01-01 2023-12-31 0001653087 alec:GskMember 2023-05-01 2023-05-31 0001653087 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001653087 alec:TwoThousandNineteenEquityIncentivePlanMember 2023-01-01 0001653087 us-gaap:RetainedEarningsMember 2020-12-31 0001653087 alec:RestrictedStockAwardsAndRestrictedStockUnitsMember 2023-01-01 2023-12-31 0001653087 alec:SouthSanFranciscoMember alec:OfficesAndLaboratoryFacilitiesMember 2022-01-01 2022-12-31 0001653087 alec:AbbVieBiotechnologyLimitedMember 2017-10-01 2017-10-31 0001653087 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001653087 alec:SouthSanFranciscoMember alec:OfficesAndLaboratoryFacilitiesMember 2023-10-31 0001653087 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001653087 alec:TwoThousandNineteenEquityIncentivePlanMember 2023-01-01 2023-12-31 0001653087 alec:GskMember 2023-01-01 2023-12-31 0001653087 srt:MaximumMember alec:AbbVieBiotechnologyLimitedMember 2023-02-28 0001653087 alec:AbbVieBiotechnologyLimitedMember 2022-12-31 0001653087 alec:GskMember 2023-09-30 0001653087 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2022-01-01 2022-12-31 0001653087 us-gaap:RevenueFromContractWithCustomerMember alec:AbbVieBiotechnologyLimitedMember 2023-01-01 2023-12-31 0001653087 alec:SouthSanFranciscoMember alec:OfficesAndLaboratoryFacilitiesMember 2022-05-31 0001653087 2023-12-31 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001653087 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001653087 alec:AbbVieBiotechnologyLimitedMember 2023-03-01 2023-03-31 0001653087 alec:NewarkCaliforniaMember alec:

View on Read The Filing